ArticleCureus2025
Correlation of Red Cell Distribution Width (RDW) With Weight Loss and Grade of Mucositis in Patients Who Underwent Head and Neck Radiotherapy: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRed cell distribution width (RDW) is an emerging biomarker associated with systemic inflammation, nutritional status, and prognosis in various cancers. However, its correlation with treatment-related toxicities such as mucositis and weight loss in head and neck cancer patients undergoing radiotherapy remains underexplored.
objectiveThis study aimed to evaluate the correlation between RDW (pre-treatment, post-treatment, and delta) with weight loss and mucositis severity in patients who received head and neck radiotherapy, with or without concurrent chemotherapy.
methodsA retrospective analysis was conducted on 165 patients treated between 2023 and 2024 at Sri Devaraj Urs Medical College, Kolar. Ethics approval was obtained from the Institutional Ethics Committee, and informed consent was waived owing to the retrospective nature of the study. Patients with recurrent disease, inflammatory or autoimmune disorders, or second malignancies were excluded. Weekly data on weight, mucositis grade, and hematological parameters, including RDW, were extracted from case records. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 26 (Released 2020; IBM Corp., Armonk, New York, United States), and Spearman correlation was used to assess associations.
resultsRDW delta showed a significant positive correlation with weight loss from week 2 to week 7, with the strongest association in week 6 (r = 0.253, p = 0.002). Logistic regression confirmed RDW delta was a statistically significant marker associated with >10% weight loss (odds ratio (OR) = 1.13, p = 0.032). In contrast, RDW showed weak and inconsistent correlations with mucositis grade, achieving significance only in week 2 (r = 0.225, p = 0.005).
conclusionRDW delta is a promising, cost-effective biomarker associated with weight loss during head and neck radiotherapy. However, its role as a marker for mucositis severity appears limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.